Teresa Lambe
Contact information
DPhil Projects
Teresa Lambe
Professor (OBE)
Honorary Officer of the Most Excellent Order of the British Empire (OBE), for services to Science and Public Health.
Vaccines are efficacious cost-effective healthcare measures and a global mainstay in protecting millions from infectious disease. The establishment of protective immune responses following vaccination and the formation of adaptive immune memory are crucial for ensuring long-lived immunity toward infectious disease.
At the Jenner Institute we use platform technologies to develop vaccines against emerging and re-emerging pathogens. The Lambe group is currently developing vaccines against a number of outbreak pathogens including Crimean-Congo haemorrhagic fever virus, Lassa virus, Nipah virus, Influenza, Ebolavirus and coronaviruses. A number of these vaccines have progressed through preclinical works and are being assessed in clinical trials.
We are particularly interested in delineating the immune response post vaccination and also post natural infection to define correlates of protection. As part of the Covid-19 vaccine trial as well as for many of these other vaccines the Lambe group has led on the development and validation of detailed immunological assays for the analysis in both vaccine volunteers and clinical patients.
We are currently focusing on developing a vaccine (ChAdOx1 nCoV-19) against SARS-CoV-2 progressing this vaccine through preclinical assessment and working with OVG on clinical trial testing.
COVID-19 Oxford Vaccine Trial
Recent publications
-
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial.
Jenkin D. et al, (2025), Lancet Microbe
-
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Feng S. et al, (2025), J Infect, 90
-
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Conlin K. et al, (2024), Vaccine, 45
-
Ebola disease: bridging scientific discoveries and clinical application.
Rojek A. et al, (2024), Lancet Infect Dis
-
A Bivalent Adenovirus-Vectored Vaccine Induces a Robust Humoral Response, but Does Not Protect Cynomolgus Macaques Against a Lethal Challenge With Sudan Virus.
van Tol S. et al, (2024), J Infect Dis, 230, 1083 - 1092